REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/25/2025
Back to search
Official data from USPTO
GENOSCIENCE PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
GENOSCIENCE PHARMA
ST13
US500000079258665Class
1, 5, 42, 44
Filing
79258665
Registration
6132420
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
08/26/2025
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
02/01/2019
Registration date
08/25/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/25/2020
Last transaction
08/26/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
34
Owner location
FR
Examiner
EULIN, INGRID
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
G. P. (pessoa física)
Representatives
James R. Robinson Robinson Law Office, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Active chemical ingredients used in the manufacture of anti-cancer drugs; chemical products intended for pharmaceutical scienceschemical additives for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industrypreservatives for use in the pharmaceutical industry; antioxidants for the manufacture of pharmaceutical products; chemical preparations for be used in the manufacture of pharmaceutical productsactive chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer-related diseases or conditions; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for industrial use; chemicals used in biotechnological manufacturing processes; diagnostic preparations and diagnostic reagents for scientific or research use; reagents and solvents for sample preparationmodification and manipulation of cellsas well as for the implementation of marking methodsseparationisolationreproduction and/or cleaning of biopolymersnucleic acidsproteinsmacromoleculesreagents for scientific use and biologically active substances for diagnostic usebiologically active enzymes and microorganisms that are aimed as sanitizing water environments and to treat the activation and optimization of biological filter systems
Class 5
Pharmaceutical preparationspharmaceutical productspharmaceutical substancespharmaceutical preparations for the treatment of cancer-related diseases or conditions; pharmaceutical preparations for cancer treatment; biopharmaceutical products for cancer treatmentbiological preparations for the treatments of cancer; pharmaceutical products for cancer treatment; pharmaceutical preparations and substances for cancer prevention; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for cancer prevention and treatment; biotechnological preparations for medical usebiological tissue cultures for medical purposes; diagnostic agents for medical use; strips for medical diagnosismedical diagnostic test strips for cancer diagnosis; diagnostic preparations for medical use; diagnostic reagents for medical use; diagnostic substances for medical use; pharmaceutical medicine products and diagnostic products for sample preparationmodification and manipulation of cells and for markingseparationisolationreproduction and/or cleaning of biopolymersnucleic acidsproteinsmacromolecules and biologically active substanceschemical reagents for medical purposes
Class 42
Development of new technology on behalf of third parties in the field of genetics and biotechnology; biotechnological processes for regulatingmodifying and characterizing of disease conditionsmedical research specialized in the biotechnological field with respect to regulatingmodifying and characterizing diseases or conditions; research and development for third parties in the field of biotechnology; manufacturing and consolidating upon request of DNAbiological organismscellsvirusespathogensspecial cells which have been genetically modified according to the specification of third parties for scientificmedical and laboratory use and for researchmedical and scientific laboratory services; gene therapy services for third partiesscientific research and product development regarding DNAbiological organismscellsvirusespathogens and special cells which have been genetically modified for scientific and medical use and for research; scientific and technological servicesresearch and design in the field of medical treatmentcancer treatment; industrial analysis and research servicestestinganalysis and evaluation of drugs for treatment of cancer and cancer-related diseases and conditions to assure compliance with industry and regulatory standards; research and development of anti-cancer drugs; development of pharmaceutical preparations and medicines; development of pharmaceutical products; development of chemical compoundscustom design and development of reagents and biochemical assays; research and development of new products for others with respect to chemical compounds for therapeutic use; pharmaceutical drug development services for anti-cancer drugs; evaluation of pharmaceutical products; research in the field of pharmaceutical productspharmaceutical research and development; pharmaceutical research and development in the field of anti-cancer drugs; pharmaceutical research and development services; pharmaceutical research; carrying out clinical trials for pharmaceutical productsconducting clinical trials for others; conducting cancer treatment clinical trials for others; provision of medical and scientific research information concerning the results of clinical trials for pharmaceutical products; laboratory research services in the field of pharmaceuticals; laboratory research services for cancer treatment; testinginspection and research services in the field of pharmaceuticals; testinginspection and research for pharmaceuticals for cancer treatment; biotechnological research services; preparation of reports in the field of biotechnology; research and development in the field of biotechnology; services provided by consultants in the field of biotechnologyscientific research consulting in the field of biotechnology; providing scientific research information in the biochemical and biotechnological fields; product design and development in the field of medical and pharmaceutical diagnostic apparatus
Class 44
Medical analysis services for diagnosing cancer; medical analysis of RNA or DNA for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis; colorectal cancer screening services; medical services for diagnosing diseases; medical diagnosis of cancer-related diseases or conditions; medical testing for the diagnosis and treatment of persons; medical analysis services for cancer diagnosis; medical testing and analysis for diagnostic or treatment purposes
Publications
History of USPTO decisions and trademark events.
31 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/03/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/16/2020
FIMP
FINAL DISPOSITION PROCESSED
12/15/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/25/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/25/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/09/2020
PUBO
PUBLISHED FOR OPPOSITION
06/09/2020
GPNX
NOTIFICATION PROCESSED BY IB
06/05/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/20/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/20/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/20/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/30/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/30/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/30/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/13/2020
GNFR
FINAL REFUSAL E-MAILED
01/13/2020
CNFR
FINAL REFUSAL WRITTEN
01/13/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/18/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/18/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/18/2019
RFNT
REFUSAL PROCESSED BY IB
07/12/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/24/2019
RFRR
REFUSAL PROCESSED BY MPU
06/24/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/04/2019
CNRT
NON-FINAL ACTION WRITTEN
06/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
05/24/2019
DOCK
ASSIGNED TO EXAMINER
05/20/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/20/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/16/2019
Continuous trademark protection
Get notified about every new filing that threatens GENOSCIENCE PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.